ClinicalTrials.gg
CompletedNCT05972174Updated Jul 16, 2025

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

A Phase 1/2 interventional study of mRNA-1018 for H5N8 and mRNA-1018 for H7N9 in Influenza, sponsored by ModernaTX, Inc.. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,504
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 23 studies in Influenza, Human by Moderna, Inc. — 2 open to participants now, 3 under way, 1 of them phase 3. Influenza, Human · Moderna, Inc..

Enrollment
9th of 23
1,504 · median 885
Started
2023
with 5 others
Phase 1/2
6 of 23
none open now
Registered
15th of 23
by date

Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 9th largest by enrollment, is one of 6 that started in 2023, is one of 6 in phase 1/2, and was the 15th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 23 studies in Influenza, Human by Moderna, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Influenza, Human by Moderna, Inc., or all of them as a file.
02

Study summary

The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial with one selected vaccine candidate. The study will be conducted in 2 Parts (Part A and Part B) that will enroll and run concurrently. Part A of the study will evaluate 4 vaccine candidates (H5N8, H7N9, H5 only, and H7 only). Part B of the study will evaluate a single vaccine candidate (H5 only-CG).

03

Conditions studied

  • Influenza

Keywords

  • Influenza vaccine
  • Moderna
  • mRNA-1018
  • Virus Diseases
  • Vaccines
  • Pandemic influenza
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and results of testing.
  • of 18 kilograms (kg)/square meter (m\^2) to 39 kg/m\^2 (inclusive) at the Screening visit.
  • For female participants of : negative pregnancy test, adequate , and not currently breastfeeding.

Key Exclusion Criteria:

  • Participant is acutely ill or febrile (body temperature ≥ 38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1.
  • History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
  • Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Participant has received systemic or immune-modifying drugs for >14 days in total within 180 days prior to Screening Visit (for ≥10 milligrams [mg]/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  • Participant has received any vaccine authorized or approved by local health agency including mRNA vaccine ≤28 days prior to study intervention (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after the study intervention.
  • Participant has participated in an interventional clinical study within 28 days prior to the Screening visit based on the medical history interview or plans to do so while participating in this study.

Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,504 participants (actual)

Study arms

  • Experimental
    Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 1

    Participants will receive mRNA-1018 for H5N8 at dose level 1 by intramuscular (IM) injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H5N8

  • Experimental
    Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 2

    Participants will receive mRNA-1018 for H5N8 at dose level 2 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H5N8

  • Experimental
    Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 3

    Participants will receive mRNA-1018 for H5N8 at dose level 3 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H5N8

  • Experimental
    Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 1

    Participants will receive mRNA-1018 for H5 only at dose level 1 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H5 Only

  • Experimental
    Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 2

    Participants will receive mRNA-1018 for H5 only at dose level 2 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H5 Only

  • Experimental
    Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 3

    Participants will receive mRNA-1018 for H5 only at dose level 3 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H5 Only

  • Experimental
    Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 1

    Participants will receive mRNA-1018 for H7N9 at dose level 1 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H7N9

  • Experimental
    Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 2

    Participants will receive mRNA-1018 for H7N9 at dose level 2 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H7N9

  • Experimental
    Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 3

    Participants will receive mRNA-1018 for H7N9 at dose level 3 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H7N9

  • Experimental
    Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 1

    Participants will receive mRNA-1018 for H7 only at dose level 1 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H7 Only

  • Experimental
    Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 2

    Participants will receive mRNA-1018 for H7 only at dose level 2 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H7 Only

  • Experimental
    Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 3

    Participants will receive mRNA-1018 for H7 only at dose level 3 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H7 Only

  • Experimental
    Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 1

    Participants will receive mRNA-1018 for H5 Only-CG at dose level 1 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H5 Only-CG

  • Experimental
    Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 2

    Participants will receive mRNA-1018 for H5 Only-CG at dose level 2 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H5 Only-CG

  • Experimental
    Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 3

    Participants will receive mRNA-1018 for H5 Only-CG at dose level 3 by IM injection on Day 1 and Day 22.

    Biological: mRNA-1018 for H5 Only-CG

Interventions

  • BiologicalmRNA-1018 for H5N8

    Sterile liquid for injection

  • BiologicalmRNA-1018 for H7N9

    Sterile liquid for injection

  • BiologicalmRNA-1018 for H5 Only

    Sterile liquid for injection

  • BiologicalmRNA-1018 for H7 Only

    Sterile liquid for injection

  • BiologicalmRNA-1018 for H5 Only-CG

    Sterile liquid for injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Up to Day 29 (7 days after each injection)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 43 (21 days after each injection)

  3. Number of Participants with AEs Leading to Discontinuation From Study

    Time frame: Day 1 to Day 205 (end of study [EoS])

  4. Number of Participants with Medically-Attended AEs (MAAEs)

    Time frame: Day 1 to Day 205 (EoS)

  5. Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Day 1 to Day 205 (EoS)

  6. Number of Participants with Adverse Events of Special Interest (AESIs)

    Time frame: Day 1 to Day 205 (EoS)

Secondary outcomes

  1. Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Days 22, 29, and 43, as Measured by Hemagglutination Inhibition (HAI) Assay

    Time frame: Days 22, 29, and 43

  2. Geometric Mean Fold Rise (GMFR) of Anti-HA Antibodies From Baseline to Days 22, 29, and 43, as Measured by HAI Assay

    Time frame: Baseline (Day 1), Days 22, 29, and 43

  3. Number of Participants With Seroconversion at Days 22, 29, and 43, as Measured by HAI Assay

    Seroconversion is defined as a Day 22, 29, or 43 titer ≥1:40 if baseline is \<1:10 or a 4-fold or greater rise if baseline is ≥1:10 in anti-HA antibodies measured by HAI assay.

    Time frame: Baseline (Day 1) to Days 22, 29, and 43

  4. Number of Participants With HAI Titer ≥ 1:40 at Days 22, 29, and 43

    Time frame: Days 22, 29, and 43

  5. GMT of Anti-Neuraminidase (NA) Antibodies at Days 22, 29, and 43, as Measured by Neuraminidase Inhibition (NAI) Assay

    Time frame: Days 22, 29, and 43

  6. GMFR of Anti-NA Antibodies From Baseline to Days 22, 29, and 43, as Measured by NAI Assay

    Time frame: Baseline (Day 1), Days 22, 29, and 43

  7. Number of Participants with a Change in the Days 22, 29, and 43 NAI Titer of at Least 2-/3-/4-Fold Rise

    Number of participants with a change in the Days 22, 29, or 43 NAI titer of at least 2-/3-/4-fold rise, defined as ≥2-/3-/4-fold of the lower level of quantitation (LLOQ) if the Day 1 titer is \<LLOQ; or ≥2-/3-/4-fold of the Day 1 titer if the Day 1 titer is ≥LLOQ.

    Time frame: Baseline (Day 1) to Days 22, 29, and 43

07

Study locations

27 sites
  • CenExel RCA
    Hollywood, Florida 33024, United States
  • Velocity Clinical Research
    Savannah, Georgia 31406, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • DM Clinical Research
    Southfield, Michigan 48076, United States
  • Velocity Clinical Research
    Lincoln, Nebraska 68510, United States
  • Velocity Clinical Research Providence
    East Greenwich, Rhode Island 02818, United States
  • DM Clinical Research
    Sugar Land, Texas 77478, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • J. Lewis Research, Inc/Jordan River Family Medicine
    South Jordan, Utah 84095, United States
  • Royal Victoria Infirmary
    Newcastle upon Tyne, England NE1 4LP, United Kingdom
  • Southampton General Hospital
    Southampton, England SO16 6YD, United Kingdom
  • University Hospitals Birmingham
    Birmingham, London B15 2TH, United Kingdom
  • Bradford Teaching Hospitals NHS Foundation Trust
    Bradford, London BD9 6RL, United Kingdom
  • University Hospitals
    Bristol, London Bs2 8DX, United Kingdom
  • Cardiff and Vale University
    Cardiff, London CF14 4XW, United Kingdom
  • Northern Care Alliance
    Salford, London M6 8HD, United Kingdom
  • Royal Cornwall Hospital
    Truro, London TR1 3LJ, United Kingdom
  • North Wales Clinical Research Centre
    Wrexham, London LL13 7YP, United Kingdom
  • Quadram Institute NNUH CRF
    Norwich, Norfolk NR4 7UQ, United Kingdom
  • Lakeside Healthcare Research Unit
    Corby, Northamptonshire NN17 2UR, United Kingdom
  • Western Hospital Edinburgh
    Edinburgh, EH4 CXU, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital
    London, SE1 7EH, United Kingdom
  • Chelsea and Westminster Hospital
    London, SW10 9NH, United Kingdom
  • St Georges Vaccine Institute Cranmer Terrace
    London, SW17 ORE, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, W1T 7HA, United Kingdom
  • Velocity Clinical Research
    North Finchley, N12 8BU, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jul 2024, 12 months.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 12 months is close to that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Aug 2, 2023
StartActual
Jul 10, 2023
Primary completionActual
Jul 16, 2024
CompletionActual
Jul 16, 2024
Results delay requested
Jul 14, 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05972174
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Aug 2, 2023
Start date
Jul 10, 2023
Primary completion
Jul 16, 2024
Completion
Jul 16, 2024
Last update
Jul 16, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion